Theratechnologies (TSE:TH) had its price target cut by National Bank Financial from C$9.75 to C$8.75 in a research report released on Tuesday, November 14th. They currently have an outperform rating on the stock. National Bank Financial also issued estimates for Theratechnologies’ FY2018 earnings at $0.14 EPS.
Separately, Scotiabank cut their target price on Theratechnologies from C$9.50 to C$9.25 and set an outperform rating for the company in a research note on Friday, September 29th.
Shares of Theratechnologies (TSE TH) traded down C$0.10 during midday trading on Tuesday, hitting C$6.85. The stock had a trading volume of 94,800 shares, compared to its average volume of 154,015. Theratechnologies has a 52 week low of C$2.61 and a 52 week high of C$8.72.
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc. and related companies with our FREE daily email newsletter.